Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina

Clinical Science

Volumn 131, Issue 12, 2017, Pages 1225-1243

  Ved, Nikita ^a,b   Hulse, Richard P ^a   Bestall, Samuel M ^a,c   Donaldson, Lucy F ^c   Bainbridge, James W ^b   Bates, David O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EVANS BLUE; STREPTOZOCIN; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; GLUCOSE BLOOD LEVEL; RECOMBINANT PROTEIN; TIGHT JUNCTION PROTEIN; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD RETINA BARRIER; CAPILLARY DENSITY; CELL PROTECTION; CONTROLLED STUDY; DIABETIC RETINOPATHY; EXTRAVASATION; FEMALE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINAL PIGMENT EPITHELIUM; TIGHT JUNCTION; UPREGULATION; ANIMAL; BLOOD; CELL CULTURE; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PERMEABILITY; RETINA BLOOD VESSEL; RETINA GANGLION CELL; RETINAL NEOVASCULARIZATION; SPRAGUE DAWLEY RAT; TIME FACTOR;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD GLUCOSE; BLOOD-RETINAL BARRIER; CELLS, CULTURED; CYTOPROTECTION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; NERVE DEGENERATION; PERMEABILITY; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RETINAL GANGLION CELLS; RETINAL NEOVASCULARIZATION; RETINAL PIGMENT EPITHELIUM; RETINAL VESSELS; TIGHT JUNCTION PROTEINS; TIGHT JUNCTIONS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85020306889     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20170102     Document Type: Article

References (63)

1. Klein, R., Klein, B.E. and Moss, S.E. (1984) Visual impairment in diabetes. Ophthalmology 91, 1-9
2. 2+-activated potassium beta 1 channel subunit in retinal arteriolar smooth muscle. Circ. Res. 100, 703-711
3. Bursell, S.E., Clermont, A.C., Kinsley, B.T., Simonson, D.C., Aiello, L.M. and Wolpert, H.A. (1996) Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 37, 886-897
4. Aiello, L.P., Avery, R.L., Arrigg, P.G., Keyt, B.A., Jampel, H.D., Shah, S.T. et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480-1487
5. Hammes, H.P. (2005) Pericytes and the pathogenesis of diabetic retinopathy. Horm. Metab. Res. 37 Suppl 1, 39-43
6. Cogan, D.G., Toussaint, D. and Kuwabara, T. (1961) Retinal vascular patterns. IV. Diabetic retinopathy. Arch. Ophthalmol. 66, 366-378 CrossRef
7. Gardner, T.W., Antonetti, D.A., Barber, A.J., LaNoue, K.F. and Levison, S.W. (2002) Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol. 47 Suppl 2, S253-S262
8. Simo, R., Sundstrom, J.M. and Antonetti, D.A. (2014) Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care 37, 893-899
9. Photocoagulation therapy for diabetic eye disease. (1985) Early Treatment Diabetic Retinopathy Study Research Group. J. Am. Med. Assoc. 254, 3086 CrossRef
10. Cheung, N., Wong, I.Y. and Wong, T.Y. (2014) Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes Care 37, 900-905
11. Stitt, A.W., Curtis, T.M., Chen, M., Medina, R.J., McKay, G.J., Jenkins, A. et al. (2016) The progress in understanding and treatment of diabetic retinopathy. Prog. Retin. Eye Res. 51, 156-186
12. Falavarjani, K.G. and Nguyen, Q.D. (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond.) 27, 787-794
13. Holz, F.G., Bellman, C., Staudt, S., Schutt, F. and Volcker, H.E. (2001) Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 42, 1051-1056
14. Shakib, M. and Cunha-Vaz, J.G. (1966) Studies on the permeability of the blood-retinal barrier. IV. Junctional complexes of the retinal vessels and their role in the permeability of the blood-retinal barrier. Exp. Eye Res. 5, 229-234
15. Cunha-Vaz, J.G. (1976) The blood-retinal barriers. Documenta ophthalmologica. Adv. Ophthalmol. 41, 287-327
16. Weinberger, D., Fink-Cohen, S., Gaton, D.D., Priel, E. and Yassur, Y. (1995) Non-retinovascular leakage in diabetic maculopathy. Br. J. Ophthalmol. 79, 728-731
17. Saint-Geniez, M., Kurihara, T., Sekiyama, E., Maldonado, A.E. and D'Amore, P.A. (2009) An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc. Natl. Acad. Sci. U.S.A. 106, 18751-18756
18. Simo, R., Lecube, A., Segura, R.M., Garcia Arumi, J. and Hernandez, C. (2002) Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 134, 376-382
19. Bates, D.O., Cui, T.G., Doughty, J.M., Winkler, M., Sugiono, M., Shields, J.D. et al. (2002) VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123-4131
20. Woolard, J., Wang, W.Y., Bevan, H.S., Qiu, Y., Morbidelli, L., Pritchard-Jones, R.O. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64, 7822-7835
21. Kawamura, H., Li, X., Goishi, K., van Meeteren, L.A., Jakobsson, L., Cebe-Suarez, S. et al. (2008) Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 112, 36-38 CrossRef
22. Perrin, R.M., Konopatskaya, O., Qiu, Y., Harper, S., Bates, D.O. and Churchill, A.J. (2005) Diabetic retinopathy is associated with a switch in splicing from anti-to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48, 2422-2427
23. Konopatskaya, O., Churchill, A.J., Harper, S.J., Bates, D.O. and Gardiner, T.A. (2006) VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol. Vis. 12, 626-632
24. Hua, J., Spee, C., Kase, S., Rennel, E.S., Magnussen, A.L., Qiu, Y. et al. (2010) Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 51, 4282-4288
25. Magnussen, A.L., Rennel, E.S., Hua, J., Bevan, H.S., Beazley Long, N., Lehrling, C. et al. (2010) VEGF-A165b is cytoprotective and antiangiogenic in the retina. Invest. Ophthalmol. Vis. Sci. 51, 4273-4281
26. Beazley-Long, N., Hua, J., Jehle, T., Hulse, R.P., Dersch, R., Lehrling, C. et al. (2013) VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in Vivo and in Vitro. Am. J. Pathol. 183, 918-929
27. Xu, Q., Qaum, T. and Adamis, A. (2001) Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest. Ophthalmol. Vis. Sci. 42, 789-794
28. Gammons, M.V., Dick, A.D., Harper, S.J. and Bates, D.O. (2013) SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 54, 5797-5806
29. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T. et al. (2012) Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676-682
30. Rennel, E.S., Hamdollah-Zadeh, M.A., Wheatley, E.R., Magnussen, A., Schuler, Y., Kelly, S.P. et al. (2008) Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur. J. Cancer 44, 1883-1894
31. Hulse, R.P., Beazley-Long, N., Ved, N., Bestall, S.M., Riaz, H., Singhal, P. et al. (2015) Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration. Clin. Sci. (Lond. 129, 741-756
32. Oltean, S., Qiu, Y., Ferguson, J.K., Stevens, M., Neal, C., Russell, A. et al. (2014) Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy. J. Am. Soc. Nephrol. 26, 1889-1904
33. Hart, W.E., Goldbaum, M., Cote, B., Kube, P. and Nelson, M.R. (1999) Measurement and classification of retinal vascular tortuosity. Int. J. Med. inform. 53, 239-252
34. Antonetti, D.A., Barber, A.J., Hollinger, L.A., Wolpert, E.B. and Gardner, T.W. (1999) Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J. Biol. Chem. 274, 23463-23467
35. Harhaj, N.S., Felinski, E.A., Wolpert, E.B., Sundstrom, J.M., Gardner, T.W. and Antonetti, D.A. (2006) VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest. Ophthalmol. Vis. Sci. 47, 5106-5115
36. Harper, S.J. and Bates, D.O. (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat. Rev. Cancer 8, 880-887
37. Titchenell, P.M., Lin, C.M., Keil, J.M., Sundstrom, J.M., Smith, C.D. and Antonetti, D.A. (2012) Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction. Biochem. J. 446, 455-467
38. Simo, R., Villarroel, M., Corraliza, L., Hernandez, C. and Garcia-Ramirez, M. (2010) The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier-implications for the pathogenesis of diabetic retinopathy. J. Biomed. Biotechnol. 2010, 190724
39. Hellstrom, M., Phng, L.K., Hofmann, J.J., Wallgard, E., Coultas, L., Lindblom, P. et al. (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776-780
40. Suchting, S., Freitas, C., le Noble, F., Benedito, R., Breant, C., Duarte, A. et al. (2007) The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl. Acad. Sci. U.S.A. 104, 3225-3230
41. Dong, X., Wang, Y.S., Dou, G.R., Hou, H.Y., Shi, Y.Y., Zhang, R. et al. (2011) Influence of Dll4 via HIF-1alpha-VEGF signaling on the angiogenesis of choroidal neovascularization under hypoxic conditions. PLoS One 6, e18481
42. Ye, X., Abou-Rayyah, Y., Bischoff, J., Ritchie, A., Sebire, N.J., Watts, P. et al. (2016) Altered ratios of pro-and anti-angiogenic VEGF-A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma. J. Pathol. 239, 139-151
43. Qaum, T., Xu, Q., Joussen, A.M., Clemens, M.W., Qin, W., Miyamoto, K. et al. (2001) VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. 42, 2408-2413
44. Aiello, L.P., George, D.J., Cahill, M.T., Wong, J.S., Cavallerano, J., Hannah, A.L. et al. (2002) Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 109, 1745-1751
45. Ishida, S., Usui, T., Yamashiro, K., Kaji, Y., Amano, S., Ogura, Y. et al. (2003) VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. 198, 483-489
46. Ishida, S., Usui, T., Yamashiro, K., Kaji, Y., Ahmed, E., Carrasquillo, K.G. et al. (2003) VEGF164 is proinflammatory in the diabetic retina. Invest. Ophthalmol. Vis. Sci. 44, 2155-2162
47. Joussen, A.M., Poulaki, V., Le, M.L., Koizumi, K., Esser, C., Janicki, H. et al. (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18, 1450-1452
48. Tang, J. and Kern, T.S. (2011) Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 30, 343-358
49. Thichanpiang, P., Harper, S.J., Wongprasert, K. and Bates, D.O. (2014) TNF-alpha-induced ICAM-1 expression and monocyte adhesion in human RPE cells is mediated in part through autocrine VEGF stimulation. Mol. Vis. 20, 781-789
50. Bates, D.O. (2010) Vascular endothelial growth factors and vascular permeability. Cardiovasc. Res. 87, 262-271
51. Kern, T.S., Miller, C.M., Tang, J., Du, Y., Ball, S.L. and Berti-Matera, L. (2010) Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop. Mol. Vis. 16, 1629-1639
52. Poulaki, V., Qin, W., Joussen, A.M., Hurlbut, P., Wiegand, S.J., Rudge, J. et al. (2002) Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J. Clin. Invest. 109, 805-815
53. Jin, K.L., Mao, X.O. and Greenberg, D.A. (2000) Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc. Natl. Acad. Sci. U.S.A. 97, 10242-10247
54. Shima, D.T., Adamis, A.P., Ferrara, N., Yeo, K.T., Yeo, T.K., Allende, R. et al. (1995) Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol. Med. 1, 182-193
55. Kern, T.S. and Barber, A.J. (2008) Retinal ganglion cells in diabetes. J. Physiol. (Lond.) 586, 4401-4408
56. Chantelau, E. and Kohner, E.M. (1997) Why some cases of retinopathy worsen when diabetic control improves. BMJ 315, 1105-1106
57. Dahl-Jorgensen, K., Brinchmann-Hansen, O., Hanssen, K.F., Sandvik, L. and Aagenaes, O. (1985) Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br. Med. J. (Clin. Res. Ed.) 290, 811-815
58. Schlamp, C.L., Montgomery, A.D., Mac Nair, C.E., Schuart, C., Willmer, D.J. and Nickells, R.W. (2013) Evaluation of the percentage of ganglion cells in the ganglion cell layer of the rodent retina. Mol. Vis. 19, 1387-1396
59. Nowak, D.G., Woolard, J., Amin, E.M., Konopatskaya, O., Saleem, M.A., Churchill, A.J. et al. (2008) Expression of pro-and anti-angiogenic isoforms of VEGF is differentially regulated by known splicing and growth factors. J. Cell Sci. 121, 3487-3495
60. Mavrou, A., Brakspear, K., Hamdollah-Zadeh, M., Damodaran, G., Babaei-Jadidi, R., Oxley, J. et al. (2014) Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene 34, 4311-4319
61. Amin, E.M., Oltean, S., Hua, J., Gammons, M.V., Hamdollah-Zadeh, M., Welsh, G.I. et al. (2011) WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 20, 768-780
62. Gammons, M.V., Lucas, R., Dean, R., Coupland, S.E., Oltean, S. and Bates, D.O. (2014) Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br. J. Cancer 111, 477-485
63. Batson, J., Toop, H.D., Redondo, C., Babaei-Jadidi, R., Chaikuad, A., Wearmouth, S.F. et al. (2017) Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease. ACS Chem. Biol. 12, 825-832